35 research outputs found
Author response for "Type 2 diabetes treatment and outcomes worldwide: A short review of the DISCOVER study programme"
Author response for "A pragmatic study of mid-mixture insulin and basal insulin treatment in patients with type 2 diabetes uncontrolled with oral antihyperglycemic medications: A lesson from real-world experience"
Effect of Dipeptidyl Peptidase-4 Inhibitors on Glucagon Level in Patients with T2DM: A Systemic Review and Meta-Analysis
Author response for "Population attributable fractions of modifiable risk factors for microvascular complications of type 2 diabetes in China: an analysis using national cross‐sectional data"
Author response for "Insulin glargine/lixisenatide fixed‐ratio combination ( <scp>iGlarLixi</scp> ) compared to premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis"
Author response for "Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A Phase <scp>III</scp> , randomised, double‐blind, placebo‐controlled, parallel study"
Author response for "Effect of empagliflozin on cardiorenal outcomes and mortality according to body‐mass index: A subgroup analysis of the EMPA‐REG OUTCOME trial with a focus on Asia"
Treatment Patterns and Glycemic Control in Older Adults with Type 2 Diabetes Mellitus Receiving Only Oral Antidiabetes Drugs in China
Background: Only a few studies have reported the use of oral antidiabetes drugs (OADs) for treating older adults with type 2 diabetes mellitus (T2DM) in China. This study assessed the status of OAD therapy and relevant factors associated with OAD treatment patterns and glycemic control among older patients. Patients and Methods: We conducted a noninterventional, observational, cross-sectional, multicenter study, which was initiated by the Chinese Diabetes Society, in which 9,872 outpatients with T2DM were recruited who received OADs only. Current antidiabetes treatment regimens and related clinical data were collected from patients' self-reporting and medical records. Participants were divided into two groups: 65 years and <65 years. All data were tabulated, and statistical analyses were performed using SPSS version 16 software (SPSS Inc., Chicago, IL). Results: Insulin secretagogues (52.6%): sulfonylureas (SU) (26.6%) and glinides (26.0%) were commonly used as monotherapy in those 65 years. The most popular OAD pattern was dual combination therapy (46.8%), with SU plus glucosidase inhibitors (25.1%) being most common in older participants. Age, diabetes duration, body mass index, achieving the glycemic control targets, and hypoglycemia were influencing factors to those 65 years in diverse treatment pattern models (P<0.05). Older patients receiving OADs with triple or more combination treatment and complications were more likely to have substandard glycemic control (hemoglobin A1c level 7%). Conclusions: The pattern of OADs alone in older adults with T2DM was significantly different from those <65 years in China. A comprehensive OAD treatment pattern or insulin combination may be necessary for better glycemic control in older patients with multiple combinations of OADs or complications.Novartis Pharma Co. Ltd., Beijing, ChinaSCI(E)[email protected]
